New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
08:13 EDTAMRNAmarin to present data showing Vascepa significantly reduced ApoC-III levels
Amarin announced the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa capsules significantly reduced apolipoprotein C-III, or ApoC-III, levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride metabolism. Steven B. Ketchum, Ph.D., president of research and development, senior vice president, Amarin stated, "The significantly reduced Apo C-III levels with Vascepa in the MARINE and ANCHOR trials add to previously reported TG- and ApoB-lowering effects in patients from these studies. We are pleased to continue to analyze and share data from these trials that support the clinical value of Vascepa as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia."
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:29 EDTAMRNOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:31 EDTAMRNAmarin granted summary judgment motion in suit against FDA over Vascepa
Subscribe for More Information
13:36 EDTAMRNAmarin surges after court sides with company on Vascepa exclusivity
Shares of Amarin Pharmaceuticals are surging higher after a U.S. district court sided with the company in its challenge of the Food and Drug Administrationís determination that Amarinís new drug, Vascepa, is not entitled to a five-year period of market exclusivity under the Federal Food, Drug, and Cosmetic Act. The court granted the company's motion for summary judgment and the decision denying Amarinís claim for exclusivity was vacated. The matter was remanded to the FDA for proceedings consistent with the court's opinion. In afternoon trading, Amarin shares jumped as high as $2.80 and are now up 22.5% to $2.39.
13:29 EDTAMRNAmarin wins district court ruling on Vascepa exclusivity
Amarin shares jumped 31% following the ruling.
May 22, 2015
10:32 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held in New York on May 27 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use